Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control-Reference-Cited by-同舟云学术

Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control

Published:2023-10 Issue:4 Volume:152 Page:876-886
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Zeng Xue,Qing Jing,Li Chi-Ming,Lu Jiamiao,Yamawaki Tracy,Hsu Yi-Hsiang,Vander Lugt Bryan,Hsu Hailing,Busby John,McDowell P.J.,Jackson David J.,Djukanovic Ratko,Matthews John G.,Arron Joseph R.,Bradding Peter,Brightling Christopher E.,Chaudhuri Rekha,Choy David F.,Cowan D.,Fowler S.J.,Hardman Timothy C.^ORCID,Harrison Tim,Howarth Peter,Lordan James,Mansur A.H.,Menzies-Gow Andrew,Pavord Ian D.,Walker Samantha,Woodcock Ashley,Heaney Liam G.^ORCID

Funder

Medical Research Council

Amgen

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference28 articles.

1. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort;Heaney;Chest,2021

2. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial;Heaney;Lancet Respir Med,2021

3. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era;Jackson;Thorax,2021

4. A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial;Hanratty;Trials,2018

5. Global Initiative for Asthma. 2021. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed November 10, 2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review on severe asthma: Cytokines, cells, triggers and multi-omics approaches;AIMS Allergy and Immunology;2024